Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. Methods We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a …

Tirzepatide is indicated to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Tirzepatide is also indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. Tirzepatide has demonstrated significant benefits in obese patients with a …